Related Experiment Video
Updated: Jun 5, 2026
07:48
Assessing Therapeutic Angiogenesis in a Murine Model of Hindlimb Ischemia
Published on: June 8, 2019
[Advance of therapeutic angiogenesis in coronary heart disease]
Insights
Therapeutic angiogenesis, the growth of new blood vessels, is key for treating ischemic diseases and tumors. This review covers its mechanisms and clinical uses in coronary heart disease.
Area of Science:
- Biomedical science
- Cardiovascular research
- Regenerative medicine
Context:
- Angiogenesis is a critical biological process implicated in various pathologies, including ischemic diseases and tumor growth.
- Coronary heart disease (CHD) presents a significant global health challenge, necessitating innovative treatment strategies.
- Therapeutic angiogenesis has emerged as a promising frontier in managing cardiovascular conditions like CHD.
Purpose:
- To provide a comprehensive review of the mechanisms underlying therapeutic angiogenesis.
- To explore the clinical applications of therapeutic angiogenesis specifically within the context of coronary heart disease.
- To synthesize current knowledge on promoting blood vessel formation for CHD treatment.
Summary:
- This review examines the fundamental biological processes of angiogenesis.
- It details the potential of therapeutic angiogenesis as a treatment modality for ischemic conditions, particularly coronary heart disease.
- Key mechanisms and established clinical applications are discussed, highlighting advancements in the field.
Impact:
- Enhances understanding of angiogenesis in cardiovascular disease.
- Informs the development of novel therapeutic strategies for coronary heart disease.
- Supports the clinical translation of angiogenesis-based therapies for ischemic conditions.
Abstract:
A Review: Angiogenesis is an important biological phenomenon existed in ischemic diseases, tumor, and other diseases. Therapeutic angiogenesis is a frontier area in the treatment of coronary heart disease. The mechanisms and clinical application of therapeutic angiogenesis in coronary heart disease were briefly reviewed in this article.
Related Concept Videos
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
01:27Coronary Artery Disease V: Interprofessional Care
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:26Angina IV: Management
IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
01:26Coronary Artery Disease II: Pathophysiology
Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
01:30Coronary Artery Disease III: Clinical Manifestations
Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...